No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 4.1M | 0 | 6.72M | 2.84M | 2.57M |
| Revenue Growth % | - | - | -1% | - | -0.58% | -0.1% |
| Cost of Goods Sold | 421.82K | 0 | 543.6K | 4.14M | 2.28M | 1.61M |
| COGS % of Revenue | - | - | - | 0.62% | 0.8% | 0.63% |
| Gross Profit | -421.82K | 4.1M | -543.6K | 2.59M | 560.36K | 959.4K |
| Gross Margin % | - | 1% | - | 0.38% | 0.2% | 0.37% |
| Gross Profit Growth % | - | 10.72% | -1.13% | 5.76% | -0.78% | 0.71% |
| Operating Expenses | 6.94M | 9.92M | 12.82M | 17.67M | 26.28M | 30.44M |
| OpEx % of Revenue | - | 2.42% | - | 2.63% | 9.25% | 11.86% |
| Selling, General & Admin | 1.8M | 2.44M | 5M | 7.99M | 13.08M | 21.95M |
| SG&A % of Revenue | - | 0.59% | - | 1.19% | 4.6% | 8.55% |
| Research & Development | 5.14M | 7.26M | 7.82M | 9.34M | 7.68M | 6.39M |
| R&D % of Revenue | - | 1.77% | - | 1.39% | 2.7% | 2.49% |
| Other Operating Expenses | 0 | 233.04K | 0 | 338.46K | 5.52M | 2.1M |
| Operating Income | -7.37M | -5.82M | -13.37M | -15.08M | -25.72M | -29.48M |
| Operating Margin % | - | -1.42% | - | -2.24% | -9.05% | -11.49% |
| Operating Income Growth % | - | 0.21% | -1.3% | -0.13% | -0.71% | -0.15% |
| EBITDA | -6.94M | -5.25M | -12.82M | -14.36M | -24.58M | -28.3M |
| EBITDA Margin % | - | -1.28% | - | -2.14% | -8.65% | -11.02% |
| EBITDA Growth % | - | 0.24% | -1.44% | -0.12% | -0.71% | -0.15% |
| D&A (Non-Cash Add-back) | 421.82K | 572.87K | 543.6K | 717.85K | 1.14M | 1.18M |
| EBIT | -7.29M | -5.82M | -12.86M | -14.77M | -24.71M | -28.87M |
| Net Interest Income | 72.35K | 22.32K | 505.37K | -126.66K | -283.04K | -1.16M |
| Interest Income | 72.35K | 22.32K | 505.37K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 126.66K | 283.04K | 1.16M |
| Other Income/Expense | 72.35K | 22.32K | 505.37K | 178.07K | 722.88K | -544.15K |
| Pretax Income | -7.29M | -5.8M | -12.86M | -14.9M | -24.99M | -30.02M |
| Pretax Margin % | - | -1.42% | - | -2.22% | -8.8% | -11.7% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -7.29M | -5.78M | -12.86M | -14.9M | -24.99M | -30.02M |
| Net Margin % | - | -1.41% | - | -2.22% | -8.8% | -11.7% |
| Net Income Growth % | - | 0.21% | -1.23% | -0.16% | -0.68% | -0.2% |
| Net Income (Continuing) | -7.29M | -5.8M | -12.86M | -14.9M | -24.99M | -30.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.20 | -0.16 | -0.35 | -0.41 | -0.70 | -0.77 |
| EPS Growth % | - | 0.2% | -1.19% | -0.17% | -0.71% | -0.1% |
| EPS (Basic) | -0.20 | -0.16 | -0.35 | -0.41 | -0.70 | -0.77 |
| Diluted Shares Outstanding | 36.7M | 36.7M | 35.77M | 35.82M | 35.93M | 38.79M |
| Basic Shares Outstanding | 36.7M | 36.7M | 35.77M | 35.82M | 35.93M | 38.79M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 8.03M | 12.15M | 40.48M | 34.07M | 6.4M | 5.7M |
| Cash & Short-Term Investments | 7.36M | 8.46M | 36.71M | 32.06M | 3.6M | 4.67M |
| Cash Only | 7.36M | 8.46M | 11.73M | 22.33M | 3.6M | 4.67M |
| Short-Term Investments | 0 | 0 | 24.98M | 9.74M | 0 | 0 |
| Accounts Receivable | 0 | 2.5M | 133K | 417.69K | 1.54M | 582.2K |
| Days Sales Outstanding | - | 222.57 | - | 22.68 | 197.25 | 82.79 |
| Inventory | 0 | 0 | 0 | 1.39M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 123.11 | - | - |
| Other Current Assets | 236.29K | 654.53K | 1.44M | 196.01K | 230.92K | 113.53K |
| Total Non-Current Assets | 2.04M | 3.25M | 13.03M | 12.74M | 22.11M | 24.54M |
| Property, Plant & Equipment | 2M | 1.62M | 1.12M | 10.8M | 20.45M | 22.91M |
| Fixed Asset Turnover | - | 2.54x | - | 0.62x | 0.14x | 0.11x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 1.6M | 11.52M | 1.6M | 1.6M | 1.6M |
| Other Non-Current Assets | 34.24K | 34.24K | 393.32K | 333.88K | 56.54K | 28.48K |
| Total Assets | 10.07M | 15.4M | 53.51M | 46.81M | 28.51M | 30.24M |
| Asset Turnover | - | 0.27x | - | 0.14x | 0.10x | 0.08x |
| Asset Growth % | - | 0.53% | 2.48% | -0.13% | -0.39% | 0.06% |
| Total Current Liabilities | 1.07M | 1M | 2.32M | 2.96M | 8.75M | 29.63M |
| Accounts Payable | 392.33K | 155.34K | 223.66K | 1.23M | 6.17M | 22.33M |
| Days Payables Outstanding | 339.49 | - | 150.18 | 108.22 | 986.68 | 5.07K |
| Short-Term Debt | 0 | 567.31K | 0 | 0 | 0 | 6.31M |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 278.43K | 297.93K | 0 | 0 | 774.94K |
| Current Ratio | 7.53x | 12.14x | 17.44x | 11.52x | 0.73x | 0.19x |
| Quick Ratio | 7.53x | 12.14x | 17.44x | 11.05x | 0.73x | 0.19x |
| Cash Conversion Cycle | - | - | - | 37.57 | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 6.42M | 6.3M | 7.38M |
| Long-Term Debt | 0 | 0 | 0 | 6.41M | 6.3M | 7.38M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 14.28K | 0 | 0 |
| Total Liabilities | 1.07M | 1M | 2.32M | 9.38M | 15.05M | 37.01M |
| Total Debt | 0 | 567.31K | 0 | 6.41M | 6.3M | 13.69M |
| Net Debt | -7.36M | -7.89M | -11.73M | -15.92M | 2.71M | 9.02M |
| Debt / Equity | - | 0.04x | - | 0.17x | 0.47x | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -119.05x | -90.86x | -25.45x |
| Total Equity | 9M | 14.4M | 51.19M | 37.43M | 13.46M | -6.77M |
| Equity Growth % | - | 0.6% | 2.56% | -0.27% | -0.64% | -1.5% |
| Book Value per Share | 0.25 | 0.39 | 1.43 | 1.04 | 0.37 | -0.17 |
| Total Shareholders' Equity | 9M | 14.4M | 51.19M | 37.43M | 13.46M | -6.77M |
| Common Stock | 472 | 1.12K | 3.58K | 3.59K | 3.6K | 4.45K |
| Retained Earnings | -9.68M | -16.72M | -30.64M | -45.54M | -70.53M | -100.56M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.1K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -6.77M | -10.43M | -10.98M | -10.39M | -22.51M | -14.23M |
| Operating CF Margin % | - | -2.54% | - | -1.55% | -7.92% | -5.54% |
| Operating CF Growth % | - | -0.54% | -0.05% | 0.05% | -1.17% | 0.37% |
| Net Income | -7.29M | -5.8M | -12.86M | -14.9M | -24.99M | -30.02M |
| Depreciation & Amortization | 421.82K | 572.87K | 543.6K | 717.85K | 1.14M | 1.18M |
| Stock-Based Compensation | 1.76K | 21.88K | 360.98K | 1.12M | 1M | 1.01M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 23.04K | -473.22K | 188.46K | 4.98M | -418 |
| Working Capital Changes | 104.17K | -5.25M | 1.46M | 2.49M | -4.64M | 13.6M |
| Change in Receivables | 0 | -2.5M | 2.37M | -284.69K | -1.12M | 953.56K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 766.39K | -628.65K | 1.89M | 418.21K | 1.62M | 11.87M |
| Cash from Investing | -1.46M | -186.68K | -35.02M | 14.71M | 3.8M | -261.62K |
| Capital Expenditures | -1.46M | -186.68K | -47.26K | -10.28M | -6.2M | -261.62K |
| CapEx % of Revenue | - | 0.05% | - | 1.53% | 2.18% | 0.1% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 164 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 13.45M | 11.72M | 49.27M | 6.27M | -14.53K | 15.57M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -6.76M | -190.55K | 0 | 2.32M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -8.23M | -10.62M | -11.02M | -20.66M | -28.72M | -14.49M |
| FCF Margin % | - | -2.59% | - | -3.07% | -10.11% | -5.64% |
| FCF Growth % | - | -0.29% | -0.04% | -0.87% | -0.39% | 0.5% |
| FCF per Share | -0.22 | -0.29 | -0.31 | -0.58 | -0.80 | -0.37 |
| FCF Conversion (FCF/Net Income) | 0.93x | 1.80x | 0.85x | 0.70x | 0.90x | 0.47x |
| Interest Paid | 0 | 0 | 0 | 126.66K | 283.04K | 569.77K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -81.03% | -49.41% | -39.22% | -33.63% | -98.23% | -897.37% |
| Return on Invested Capital (ROIC) | - | -107.17% | -43.62% | -37.09% | -102.37% | -240.08% |
| Gross Margin | - | 100% | - | 38.48% | 19.72% | 37.38% |
| Net Margin | - | -140.98% | - | -221.67% | -879.52% | -1169.7% |
| Debt / Equity | - | 0.04x | - | 0.17x | 0.47x | - |
| Interest Coverage | - | - | - | -119.05x | -90.86x | -25.45x |
| FCF Conversion | 0.93x | 1.80x | 0.85x | 0.70x | 0.90x | 0.47x |
| Revenue Growth | - | - | -100% | - | -57.72% | -9.68% |
HCW Biologics Inc. (HCWB) reported $0.4M in revenue for fiscal year 2024.
HCW Biologics Inc. (HCWB) saw revenue decline by 9.7% over the past year.
HCW Biologics Inc. (HCWB) reported a net loss of $12.1M for fiscal year 2024.
HCW Biologics Inc. (HCWB) has a return on equity (ROE) of -897.4%. Negative ROE indicates the company is unprofitable.
HCW Biologics Inc. (HCWB) had negative free cash flow of $13.0M in fiscal year 2024, likely due to heavy capital investments.